Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 29

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 29
---
 date of this
registration statement, of 6,226,400,000 Ordinary Shares pursuant to the terms of the ELOC
to the Investor, including 46,400,000 Ordinary Shares to the Investor in satisfaction of
a commitment fee, resulting in $0.3 million in gross proceeds, our pro forma net tangible
book value as of June 30, 2025 would have been $8.31 million, or $12.19 per Depositary Share.

After
giving effect to the sale of all Units by us in this offering at an assumed public offering
price of $4.07 per Unit, and assuming no sale of any Pre-Funded Units and no exercise of
the Series L Warrants and Placement Agent Warrants, and after deducting estimated placement
agent fees and estimated offering expenses payable by us, our as adjusted net tangible book
value as of June 30, 2025 would have been approximately $23.76 million, or $4.65 per
Depositary Share. This represents an immediate decrease in net tangible book value of $7.54
per Depositary Share to our existing shareholders and an immediate accretion of $0.58 per
Depositary Share to investors purchasing Units in this offering. The final public offering
price will be determined through negotiation between us and the placement agent in the offering
and may be at a discount to the current market price. Therefore, the assumed public offering
price used throughout this prospectus may not be indicative of the final public offering
price.

The following table illustrates
this dilution on a per Depositary Share basis:

|                                                                                                                                      |     | As at June 30, 2025   |       |   |
|:-------------------------------------------------------------------------------------------------------------------------------------|:----|:----------------------|------:|:--|
|                                                                                                                                      |     | Per Depositary Shares |       |   |
| Assumed public offering price per Depositary Share                                                                                   |     | $                     |  4.07 |   |
| Historical net tangible book value per Depositary Share as of June 30, 2025                                                          |     | $                     | 12.82 |   |
| Decrease per Depositary Share attributable to pro forma adjustment                                                                   
 above                                                                                                                                |     | $                     | (0.62 | ) |
| Pro forma net tangible book value per Depositary Share as of June                                                                    
 30, 2025                                                                                                                             |     | $                     | 12.19 |